28 Jul

Eli Lilly’s Elanco in 2Q17

WRITTEN BY Mike Benson


Elanco is part of Eli Lilly and Company’s (LLY) Animal Health segment. Elanco includes products from the companion animal product portfolio as well as the food and other products portfolio for animals. Elanco’s revenues fell 9.0% to $784.8 million in 2Q17 compared to $859.8 million in 2Q16.

Eli Lilly’s Elanco in 2Q17

The above graph shows revenues for Elanco over the last eight quarters. The segment contributed ~13.5% to Lilly’s total revenues in 2Q17.

Revenues for Animal Health segment

Eli Lilly’s US Animal Health sales fell 9.0% to $406.5 million in 2Q17. Animal Health sales outside the US markets fell 9.0% to $378.3 million, including revenues from Novartis (NVS) Animal Health. US revenues fell due to a 23.0% fall in the sales of food and other products following the competition as well as market access pressure for cattle and swine products. US companion animal products reported a 9.0% rise in revenues due to the inclusion of the Boehringer Ingelheim Vetmedica’s US Feline, Canine, and Rabies Vaccines portfolio. For international revenues, the animal food products and companion products reported falling revenues due to lower sales.

Companion animal products

Companion animal products reported a marginal rise in revenues to $311.8 million in 2Q17 compared to $309.8 million in 2Q16. That includes a 9.0% rise in US sales of companion animal products to $222.8 million and a fall of 16.0% in sales of companion animal products outside the US markets to $88.9 million.

Food and other products

Revenues for food and other products were $473.1 million in 2Q17, a 14.0% fall compared to $550.0 million in 2Q16. Revenues included a fall of 23.0% in US sales, a 7.0% fall in international sales, a 5.0% operational decline, and a 2.0% negative impact of foreign exchange.

Other companies such as Merial, a Sanofi (SNY) company; Zoetis (ZTS), the animal health arm of Pfizer (PFE); and Merck & Co.’s (MRK) animal health segment compete with Lilly on certain product mixes.

To divest the company-specific risks, you can consider the Vanguard Healthcare ETF (VHT), which holds 2.4% of its total assets in Eli Lilly. VHT also holds 10.0% in Johnson & Johnson (JNJ), 3.2% in AbbVie (ABBV), and 2.7% in Allergan (AGN).

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.